Wellington Management Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Wellington Management Group’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,407,159	Closed	-$4.69M	–	2159
2019 Q3	$4.69M	Sell	1,407,159 -42,035	-3%	-$168K	﹤0.01%	1372
2019 Q2	$7.17M	Sell	1,449,194 -52,964	-4%	-$281K	﹤0.01%	1293
2019 Q1	$9.31M	Sell	1,502,158 -8,596	-0.6%	-$41.5K	﹤0.01%	1225
2018 Q4	$5.09M	Sell	1,510,754 -138,999	-8%	-$649K	﹤0.01%	1377
2018 Q3	$10.7M	Sell	1,649,753 -344,951	-17%	-$2.56M	﹤0.01%	1261
2018 Q2	$15.3M	Sell	1,994,704 -77,779	-4%	-$1.12M	﹤0.01%	1164
2018 Q1	$46.3M	Buy	2,072,483 +197,621	+11%	+$4.39M	0.01%	812
2017 Q4	$23.9M	Sell	1,874,862 -6,100	-0.3%	-$89.7K	0.01%	1014
2017 Q3	$29.3M	Sell	1,880,962 -559,754	-23%	-$7.91M	0.01%	926
2017 Q2	$34.2M	Buy	2,440,716 +857,531	+54%	+$18.4M	0.01%	845
2017 Q1	$34.8M	Buy	+1,583,185	New	+$33.5M	0.01%	846

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wellington Management Group's JNCE Position: Q4 2019 in Review

Wellington Management Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2019, closing a stake of 1,407,159 shares — an estimated $4.69M sold.

Wellington Management Group first reported a position in JNCE in Q1 2017 and held it in 11 quarters. The position peaked at $46.3M in Q1 2018. 100 funds tracked by Wall St. Rank hold JNCE as of Q4 2019.

Wellington Management Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Wellington Management Group sold 1,407,159 Jounce Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $4.69M.
Wellington Management Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 11 quarters.
Wellington Management Group's Jounce Therapeutics, Inc. Common Stock position peaked at $46.3M in Q1 2018.
100 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Wellington Management Group's 13F filing for Q4 2019, filed 11 Feb 2020.